PLTR
Palantir
-- 70.960 SMCI
Super Micro Computer
-- 40.210 NVDA
NVIDIA
-- 140.260 TSLA
Tesla
-- 351.420 INTC
Intel
-- 22.470 
NEWS
IGC Pharma Advances IGC-AD1 as a Potential Alzheimer's Therapy Addressing Cognitive Impairment and Underlying Disease Pathology
Monday, 2nd December at 8:30 am
New trials to evaluate IGC-AD1's potential impact on amyloid plaque, tau tangles, and cognitive decline in Alzheimer's disease
Expanded research positions IGC-AD1 as a potential treatment targeting the underlying disease pathology of Alzheimer's
POTOMAC, MARYLAND / ACCESSWIRE / December 2, 2024 / IGC Pharma, Inc. (NYSE: IGC) ("IGC Pharma" or the "Company") announced today an expansion of its clinical research program for IGC-AD1, an investigational treatment for Alzheimer's disease.
Building on Phase 2 interim results demonstrating reductions in agitation and cognitive improvement, the Company is initiating new trials to evaluate IGC-AD1's potential as a disease-modifying therapy.
The expanded research will explore how IGC-AD1's dual-action mechanism-combining anti-neuroinflammatory properties with amyloid- and tau-targeting effects-may slow the progression of Alzheimer's disease.
These trials will evaluate critical outcomes, including cognitive function and biological markers associated with Alzheimer's, such as amyloid and tau levels, at multiple time points.
Building on previously announced preclinical data showing IGC-AD1's impact on amyloid plaques and spatial memory, these investigations aim to explore its potential to influence key pathological features of Alzheimer's disease.
Disclaimer: Community is offered by Moomoo Technologies Inc. and is for educational purposes only.
Read more
Comment
Sign in to post a comment